



## Identification Number: FDA/CSD/CPE/PRS/21/008 TYPE OF COMMUNICATION: COVID-19 VACCINE SAFETY

22<sup>nd</sup> July 2021

### JOINT COVID-19 VACCINE SAFETY REVIEW COMMITTEE-SAFETY MONITORING UPDATE 8

The Food and Drugs Authority (FDA) continues to monitor the safety of COVID-19 vaccines deployed during the pandemic using proactive strategies, to ensure safety of all vaccine recipients.

As at 14<sup>th</sup> July 2021 two vaccines namely, Covishield and Sputnik V have been deployed in Ghana to combat the pandemic. To date, 865,422 first doses and 405,971 second doses of Covishield have been administered; while 7,940 first doses of Sputnik V have been administered.

Generally, the most commonly reported side effects for both vaccines are headache, fever, chills, pain at injection site and body pains which resolved within a day or two.

The FDA's Joint COVID-19 Vaccine Safety Review Committee (JCVSRC) at the 9<sup>th</sup> meeting held on Friday, 16<sup>th</sup> July 2021,

reviewed all safety reports available from the FDA's safety monitoring activities of Covishield and Sputnik V as well as from international sources.

The JCVSRC recommends the continued use of the vaccines to combat the pandemic since the vaccines have shown a very high level of protection against symptomatic infections with COVID-19.

The FDA will continue to proactively monitor the safety of all vaccines issued with Emergency Use Authorization to be deployed during the pandemic.



**DELESE A. A. DARKO (MRS)**

**CHIEF EXECUTIVE OFFICER**